5-hydrazinocarbonylthiophene-2-carboxylic acid 4-picolylamide | 891778-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-hydrazinocarbonylthiophene-2-carboxylic acid 4-picolylamide
• 英文别名: 5-(hydrazinecarbonyl)-N-(pyridine-4-ylmethyl)thiophene-2-carboxamide；5-(hydrazinecarbonyl)-N-(pyridin-4-ylmethyl)thiophene-2-carboxamide
• CAS: 891778-92-0
• 化学式: C₁₂H₁₂N₄O₂S
• 分子量: 276.319
• InChiKey: QXTQOHHQTDSXHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-hydrazinocarbonylthiophene-2-carboxylic acid 4-picolylamide 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 27.0h， 以62%的产率得到4-[{5-(methoxycarbonyl) thiophene-2-carboxamido}methyl]pyridine 1-oxide
  参考文献：
  名称：

  WO2007/10954

  摘要：

  公开号：

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
  申请人：Shigeta Yukihiro

  公开号：US20120209005A1

  公开（公告）日：2012-08-16

  Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 is an aryl group fused to a saturated ring or the like, A, B, L 1 , R 2 , L 2 , L 3 , Y, L 4 , R 3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了对激活血小板生成素受体有效的疾病的预防、治疗或改善有用的融合杂环化合物。代表式(I)的化合物（其中R1是与饱和环或类似物融合的芳基，A、B、L1、R2、L2、L3、Y、L4、R3和X在描述中有定义），该化合物的互变异构体、前药或药用可接受的盐或其溶剂化物。
• THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
  申请人：Miyaji Katsuaki

  公开号：US20090118500A1

  公开（公告）日：2009-05-07

  A compound represented by the formula (I) (wherein R 1 , R 2 , R 3 and R 4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  化合物的化学式为（I）（其中R1，R2，R3和R4的定义见说明），该化合物的互变异构体、前药或药物可接受的盐或其溶剂化物。
• HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
  申请人：Miyaji Katsuaki

  公开号：US20090253751A1

  公开（公告）日：2009-10-08

  Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 , R 2 , R 3 , L 1 , L 2 , X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了一种用于预防、治疗或改善激活血小板生成素受体有效对抗的疾病的化合物。该化合物由式(I)所表示（其中R1、R2、R3、L1、L2、X和Y在描述中被定义），该化合物的互变异构体、前药或药物可接受的盐或其溶剂化物。
• Pyrazole compounds and thrombopoietin receptor activators
  申请人：Nissan Chemical Industries, Ltd.

  公开号：US07960425B2

  公开（公告）日：2011-06-14

  A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  化合物的化学式为（I）（其中R1，R2，R3和R4的定义见说明），该化合物的互变异构体、前药或药学上可接受的盐或其溶剂化物。
• Fused heterocyclic compounds and thrombopoietin receptor activators
  申请人：Shigeta Yukihiro

  公开号：US08889732B2

  公开（公告）日：2014-11-18

  Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R1 is an aryl group fused to a saturated ring or the like, A, B, L1, R2, L2, L3, Y, L4, R3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了对激活血小板生成素受体有效的预防、治疗或改善疾病有用的融合杂环化合物。化合物由式(I)表示（其中R1是与饱和环或类似物融合的芳基基团，A、B、L1、R2、L2、L3、Y、L4、R3和X在说明中定义），化合物的互变异构体、前药或药学上可接受的盐或其溶剂化物。